Mirion Technologies, Inc. (MIR) Stock Analysis
Industrials · Specialty Industrial Machinery
Hold if already holding. Not a fresh buy at $16.68, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors.
Mirion Technologies provides radiation detection, measurement, analysis and monitoring solutions through Nuclear & Safety and Medical segments, serving nuclear power plants (in 98%+ of global plants), cancer centers (80%+), 23 of 32 NATO militaries, and industrial customers.... Read more
Hold if already holding. Not a fresh buy at $16.68, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 43d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About Mirion Technologies, Inc.
About Mirion Technologies, Inc.
Mirion Technologies' Nuclear & Safety and Medical segments drew approximately 48% of fiscal 2025 net sales from customers in the United States and Canada, 33% from Europe, and 17% from Asia Pacific, with the company's radiation monitoring solutions installed in more than 98% of nuclear power plants globally. Mirion closed two acquisitions in 2025: Certrec in July (regulatory compliance software for the nuclear sector) and Paragon Energy Solutions in December (obsolescence and parts availability for NPPs), both integrated into Nuclear & Safety.
The Nuclear & Safety segment serves the full lifecycle of nuclear power plants — construction, operation, decommissioning — as well as laboratories, defense forces including 23 of 32 NATO militaries, and industrial end markets. Over 80% of Nuclear & Safety's power end-market revenue comes from the installed base of existing NPPs, driving replacement and service cycles tied to the 40- to 100-year operating life of a nuclear plant. The Medical segment serves cancer centers with radiation therapy quality assurance systems and nuclear medicine tools, and provides dosimetry services badging over one million wearers globally. Service revenue represented 25.4% of consolidated revenue in fiscal 2025, providing a recurring revenue base. The company relies on third-party suppliers including sole or limited-source providers for certain components, exposing it to supply disruption risk; sales cycles for NPP new-build projects range from 12 to 60 or more months.
Show full overview
A substantial portion of Mirion's U.S. revenue comes from contracts with U.S. governmental customers or their contractors — including the Departments of Energy, State, Defense, and Homeland Security — making government budget cycles and procurement timelines a key driver of order flow. Escalation of U.S. or EU sanctions targeting Russian state-owned enterprises involved in nuclear construction could further complicate revenue recognition in the nuclear segment; the company has already experienced delayed contract payments and export license requirements in Russia and will continue to navigate a complex sanctions regime.
See also: Industrials · Specialty Industrial Machinery
From Mirion Technologies, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Mirion Technologies, Inc.
Latest news
- NEWS Mirion Technologies, Inc. (MIR) Q1 earnings meet estimates - MSN — MSN neutral
- NEWS Mirion Technologies (MIR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS MIR Mirion Technologies posts 6.9% Q4 2025 EPS miss against estimates, shares fall 1.68% in today’s trading. - Cổng thôn — Cổng thông tin điện tử Tỉnh Sơn La negative
- NEWS Studio Mir Unveils Main Trailer for "Devil May Cry" Season 2... Global Release on May 12 - 아시아경제 — 아시아경제 neutral
- NEWS Mirion Technologies, Inc. (MIR) Q1 Earnings Meet Estimates - Yahoo Finance — Yahoo Finance neutral
Generated 2026-06-17T09:02:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicUnited States and Canada48%10-K Item 1: 'Sales to customers inside the United States and Canada accounted for approximately 48% of total revenue for fiscal 2025'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWBoard approved a special one-time grant of 2,500,000 performance-vesting stock options to CEO Thomas Logan on April 9, 2026, designed to retain and incentivize him over the next five years with TSR-linked vesting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $16.68, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $24.27 (+45.5%), stop $15.50 (−7.6%), A.R:R 4.3:1. Score 5.6/10, moderate confidence.
Take-profit target: $24.27 (+45.6% upside). Target $24.27 (+45.5%), stop $15.50 (−7.6%), A.R:R 4.3:1. Stop-loss: $15.50.
Negative momentum; Elevated risk factors; Below 200-MA, MA slope -2.1%/30d (confirmed downtrend).
Mirion Technologies, Inc. trades at a P/E of 165.6 (forward 25.3). TrendMatrix value score: 5.8/10. Verdict: Hold.
15 analysts cover MIR with a consensus score of 4.1/5. Average price target: $28.
What does Mirion Technologies, Inc. do?Mirion Technologies provides radiation detection, measurement, analysis and monitoring solutions through Nuclear &...
Mirion Technologies provides radiation detection, measurement, analysis and monitoring solutions through Nuclear & Safety and Medical segments, serving nuclear power plants (in 98%+ of global plants), cancer centers (80%+), 23 of 32 NATO militaries, and industrial customers. Revenue is globally distributed: US+Canada ~48%, Europe ~33%, Asia-Pacific ~17% of FY2025 total; service revenue = ~25%.